| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/13/2011 | WO2011004117A1 Method and pharmaceutical compositions for trans-buccal mucosa treatment of postprandial hyperglycaemia in type ii diabetes |
| 01/13/2011 | WO2011004051A1 Gene therapy compositions for preventing and/or treating autoimmune diseases |
| 01/13/2011 | WO2011003995A1 Product for the storage of freeze-dried lactic acid bacteria mixed with a powder for an oral rehydration solution |
| 01/13/2011 | WO2011003823A1 Slow-acting insulin preparations |
| 01/13/2011 | WO2011003820A1 Heat- and vibration-stable insulin preparations |
| 01/13/2011 | WO2011003418A1 Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors |
| 01/13/2011 | WO2011003284A1 Compound and preparation method and use thereof |
| 01/13/2011 | WO2010135714A3 Methods for modulating adipocyte expression using microrna compositions |
| 01/13/2011 | WO2010130771A3 Compositions and methods for inhibiting expression of glucocorticoid receptor (gcr) genes |
| 01/13/2011 | WO2010107866A3 Catecholamine derivatives for obesity and neurological disorders |
| 01/13/2011 | US20110009955 Compounds and method for coating surfaces in a hemocompatible manner |
| 01/13/2011 | US20110009625 Novel compounds |
| 01/13/2011 | US20110009463 Geranylgeranyl transferase inhibitors and methods of making and using the same |
| 01/13/2011 | US20110009455 5-Oxo-2,3,4,5-tetrahydro-benzo[b]oxepine-4-carboxylic acid amides and 2,3-Dihydro-benzo[b]oxepine-4-carboxylic acid amides for treatment and prevention of Diabetes Typ 1 and 2 |
| 01/13/2011 | US20110009449 N-aryl-n-piperidin-4-yl-propionamide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 01/13/2011 | US20110009448 Compound |
| 01/13/2011 | US20110009447 Substituted Benzoic Acid Amides and Use thereof for the Inhibition of Angiogenesis |
| 01/13/2011 | US20110009443 Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors |
| 01/13/2011 | US20110009439 Indene derivatives as pharmaceutical agents |
| 01/13/2011 | US20110009437 Carboxamide-heteroaryl derivatives for the treatment of diabetes |
| 01/13/2011 | US20110009434 Crystals of isopropyl ester of n-(2,6-dichlorobenzoyl)-4-[6-(methylamino)methyl -1-methyl-2,4-dioxo-1,4-dihydroquinazoline-3(2h)-yl]-l- phenylalanine hydrochloride, production method thereof and use thereof |
| 01/13/2011 | US20110009433 Bicyclic pyrrole compound |
| 01/13/2011 | US20110009427 Aryl pyrimidine derivatives, preparation methods and pharmaceutical uses thereof |
| 01/13/2011 | US20110009426 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation thereof and therapeutic application thereof as urotensin ii receptor antagonists |
| 01/13/2011 | US20110009417 Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes |
| 01/13/2011 | US20110009414 Heterocyclic derivatives and their use as therapeutic agents |
| 01/13/2011 | US20110009409 Dual-acting pyrazole antihypertensive agents |
| 01/13/2011 | US20110009402 Cyclic Inhibitors of 11Beta-Hydroxysteroid Dehydrogenase 1 |
| 01/13/2011 | US20110009400 Bicyclic derivatives of azabicyclic carboxamides, preparation thereof and therapeutic use thereof |
| 01/13/2011 | US20110009396 Tricyclic compounds for the treatment of inflammatory disorders |
| 01/13/2011 | US20110009391 Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application |
| 01/13/2011 | US20110009386 Furo[3, 2-b] pyrr0l-3-0nes as cathespin s inhibitors |
| 01/13/2011 | US20110009384 Fused ring compounds as partial agonists of ppar-gamma |
| 01/13/2011 | US20110009382 Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles |
| 01/13/2011 | US20110009381 Solubilized thiazolopyridines |
| 01/13/2011 | US20110009377 Azetidine derivatives, their preparation and their application in therapy |
| 01/13/2011 | US20110009365 Derivatives of indole-2-carboxamides and of azaindole-2-carboxamides substituted with a silanyl group, preparation thereof and therapeutic use thereof |
| 01/13/2011 | US20110009359 Use of non-digestible carbohydrates for improving intestinal microbiota |
| 01/13/2011 | US20110009358 Agent for suppressing glucose level increase, agent for suppressing body fat accumulation and food compound |
| 01/13/2011 | US20110009356 Novel phosphorus-containing prodrugs |
| 01/13/2011 | US20110009347 Combination therapy for the treatment of diabetes |
| 01/13/2011 | US20110009321 Nasal calcitonin formulations containing chlorobutanol |
| 01/13/2011 | US20110009316 Proteolysis resistant active vegf |
| 01/13/2011 | US20110009315 Long-acting transient polymer conjugates of exendin |
| 01/13/2011 | US20110009314 Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof |
| 01/13/2011 | US20110009313 Polyethylene glycolated lactoferrin complex and method of producing the same |
| 01/13/2011 | US20110009312 Albumin Fusion Proteins |
| 01/13/2011 | US20110008486 Agent for suppressing glucose level increase, agent for suppressing body fat accumulation and food compound |
| 01/13/2011 | US20110008461 Inhibitor scaffold for the inhibition of the enzyme phosphoenolpyruvate carboxykinase |
| 01/13/2011 | US20110008457 Compositions and methods for modulating lipid composition |
| 01/13/2011 | US20110008452 Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance |
| 01/13/2011 | US20110008448 Diketopiperazine Salts for Drug Delivery and Related Methods |
| 01/13/2011 | US20110008423 Pharmaceutical compositions comprising granules of purified microbial lipase and methods for preventing or treating digestive disorders |
| 01/13/2011 | US20110008422 System for delivery of protein in insoluble fibrillar or aggregate form |
| 01/13/2011 | US20110008359 Monoclonal antibodies against angptl4 |
| 01/13/2011 | US20110008357 Antibodies that bind il-18 and methods of inhibiting il-18 activity |
| 01/13/2011 | US20110008352 Toll-Like Receptor 3 Antagonists |
| 01/13/2011 | US20110008341 Polypeptides and methods for making the same |
| 01/13/2011 | US20110008338 Treatment of Autoimmune Diseases |
| 01/13/2011 | US20110008337 Treatment of Autoimmune Diseases |
| 01/13/2011 | US20110008336 Treatment of Autoimmune Diseases |
| 01/13/2011 | US20110008328 Method for controlling glucose uptake and insulin sensitivity |
| 01/13/2011 | US20110008324 Antibody Selective for a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor and Uses Thereof |
| 01/13/2011 | US20110008308 Composition for hair, skin, nails |
| 01/13/2011 | US20110008301 Human adipose derived insulin making mesenchymal stem cells for treating diabetes mellitus |
| 01/13/2011 | US20110008300 Cryopreservation of Adipose Tissue for the Isolation of Mesenchymal Stem Cells |
| 01/13/2011 | US20110008298 Method of deriving progenitor cell line |
| 01/13/2011 | US20110008297 Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling |
| 01/13/2011 | US20110008259 Modulators of cystic fibrosis transmembrane conductance regulator |
| 01/13/2011 | US20110008250 Treatment of Autoimmune Diseases |
| 01/13/2011 | US20110005947 Inhibitors of jak |
| 01/13/2011 | CA2767811A1 Combination therapy for the treatment of diabetes |
| 01/13/2011 | CA2767168A1 Sodium thiosulfate-containing pharmaceutical compositions |
| 01/13/2011 | CA2767079A1 Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors |
| 01/13/2011 | CA2760008A1 Product for the storage of freeze-dried lactic acid bacteria mixed with a powder for an oral rehydration solution |
| 01/12/2011 | EP2272985A1 Antisense modulation of apolipoprotein (A) expression |
| 01/12/2011 | EP2272869A2 Angiopoietin-2 specific binding agents |
| 01/12/2011 | EP2272848A1 Xanthine derivatives as selective HM74A agonists |
| 01/12/2011 | EP2272844A1 Five-membered ring compound |
| 01/12/2011 | EP2272843A1 Quinoline compound |
| 01/12/2011 | EP2272841A1 Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor |
| 01/12/2011 | EP2272835A1 Novel five-membered ring compound |
| 01/12/2011 | EP2272834A1 Benzoyl amino heterocyclyl compounds as glucokinase (GLK) activators |
| 01/12/2011 | EP2272825A2 N-Protected amino hydroxy adamantane carboxylic acid and process for its preparation |
| 01/12/2011 | EP2272822A1 Inhibitor of plasminogen activator inhibitor-1 |
| 01/12/2011 | EP2272524A2 Y2 selective receptor agonists for therapeutic interventions |
| 01/12/2011 | EP2272521A1 Ketone accumulation inhibitor |
| 01/12/2011 | EP2272513A1 Pharmaceutical compositions for treating cancer |
| 01/12/2011 | EP2272512A1 Pharmaceutical compositions for treating cancer |
| 01/12/2011 | EP2272501A1 Polymorphs of sodium 4-((4-chloro-2-hydroxybenzoyl) amino) butanoate |
| 01/12/2011 | EP2272382A1 Composition for promotion of bone growth and maintenance of bone health, comprising soybean or soybean extracts |
| 01/12/2011 | EP2271929A1 Use of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions |
| 01/12/2011 | EP2271646A1 Apoptosis signal-regulating kinase 1 inhibitors |
| 01/12/2011 | EP2271643A1 Compounds |
| 01/12/2011 | EP2271632A1 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as hdl-cholesterol raising agents |
| 01/12/2011 | EP2271629A1 Substituted pyrimidin-5-carboxamides 281 |
| 01/12/2011 | EP2271622A2 Heteroaryl derivatives as cftr modulators |
| 01/12/2011 | EP2271619A1 Compounds and compositions as modulators of gpr119 activity |
| 01/12/2011 | EP2271405A2 Nip thiazole derivatives as inhibitors of 11-beta-hydorxysteroid dehydrogenase-1 |
| 01/12/2011 | EP2271327A1 Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and beta-cell dysfunction |